



Pharmaceuticals, Inc.

Member of Cosmo Pharmaceuticals NV Group

ABOUT ARIES PHARMACEUTICALS

Aries Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on commercializing best-in-class gastroenterology products for the U.S. market. The company's products have the potential to improve patient outcomes in endoscopy as well as in the treatment of select gastrointestinal diseases. Aries, a wholly owned subsidiary of Cosmo Pharmaceuticals, anticipates commercializing up to four products in the U.S. market over the next two years, including two products that utilize Cosmo's proprietary Multi Matrix MMX® technology to deliver active pharmaceutical ingredients directly targeted to the colon.

MISSION

At Aries, we have an overarching mission to help prevent and lower the risk for developing colon cancer, as well as offering solutions for the treatment of selected gastrointestinal diseases.

KEY FACTS

- Founded in 2016
- Privately held, wholly owned subsidiary of Cosmo Pharmaceuticals
- First product, Eleview™, an FDA 510(k) cleared class II medical device, launching May 2017

LEADERSHIP TEAM

- **Tom Joyce**
President and Chief Executive Officer
- **Jon Hee**
Chief Commercial Officer
- **Blake Boland**
Senior Vice President of Sales
- **David Kriesel**
Executive Director, Medical Affairs
- **Teri Chuppe**
Vice President, Controller
- **Mike Walther**
Vice President, Marketing

BOARD OF DIRECTORS

- **Tom Joyce**
President and Chief Executive Officer, Aries
- **Niall Donnelly**
Non-Executive Director and Chief Financial Officer, Cosmo Pharmaceuticals NV
- **Hans Christoph Tanner**
Non-Executive Director, Head of Transactions Office and Head of Investor Relations, Cosmo Pharmaceuticals NV



ARIES PIPELINE

AS OF APRIL 2017

APPROVED

Eleview™ is an injectable composition device patented by Cosmo Pharmaceuticals NV.

Eleview™



IN DEVELOPMENT

LuMeBlue™ is a novel patented application of methylene blue.

LuMeBlue™



Rifamycin SV MMX® is a patented pharmaceutical product employing rifamycin SV engineered with MMX® technology.

Rifamycin SV MMX®



Remimazolam is a patented ultra-short-acting intravenous benzodiazepine sedative/anesthetic.

Remimazolam

